摘要
目的:探讨运用经方干预治疗外寒内饮型慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者的临床疗效。方法:69例AECOPD患者随机分为经方组35例,常规组34例。两组患者均给予常规基础治疗,常规组在基础治疗基础上给予甲泼尼龙注射液;经方组在基础治疗基础上给予小青龙汤加石膏汤(3 d),加味苓桂术甘汤(4 d)。治疗后,比较两组患者临床疗效、住院时间,超敏C-反应蛋白(h-C-reaction protein,hCRP)、白细胞、降钙素原(procalcitonin,PCT)水平,肺功能,BODE评分。结果:(1)炎症指标:治疗前,经方组与常规组白细胞、h-CRP、PCT水平比较,差异无统计学意义(P> 0. 05);治疗后,两组患者白细胞、h-CRP、PCT水平均明显下降,且经方组优于常规组,差异均有统计学意义(P <0. 05)。(2)BODE评分:治疗前,经方组与常规组呼吸困难分级及6分钟步行距离比较,差异无统计学意义(P> 0. 05);治疗后,经方组以上指标明显优于常规组(P <0. 01)。(3)肺功能:治疗前,两组患者第1秒用力呼气量(forced expiratory volume 1 second,FEV1)、用力肺活量(forced vital capacity,FVC)、FEV1/FVC比较,差异均无统计学意义(P <0. 05);治疗后,经方组FEV1、FVC、FEV1/FVC均优于常规组,差异均有统计学意义(P <0. 01)。(4)住院时间及费用:经方组住院时间及住院费用均明显低于常规组,差异均有统计学意义(P <0. 05)。结论:温阳化饮经方治疗AECOPD疗效显著,可显著降低患者炎症因子水平,改善患者肺功能。
Objective: To observe the clinical efficacy of sequential therapy of acute exacerbation of chronic obstructive pulmonary disease with syndrome of external cold and internal fluid with classical prescriptions. Methods: 69 patients with AECOPD were randomly divided into classical prescription group( 35 cases) and routine group( 34 cases). Both groups were given routine basic treatment,while the routine group was given methylprednisolone injection on the basis of basic treatment; the classical prescription group was given Xiaoqinglong Decoction,Shigao Decoction( 3d) and Linggui Zhugan Decoction( 4d) on the basis of basic treatment. After treatment,the clinical efficacy,hospitalization time,the levels of h-C-reactive protein( h-CRP),white blood cells,procalcitonin( PCT),lung function and BODE scores were compared between the two groups. Results: ①Inflammation indicators: before treatment,there was no significant difference in leucocyte,h-CRP and PCT levels between the classical prescription group and the routine group( P > 0. 05); after treatment,the leucocyte,h-CRP and PCT levels of the two groups were significantly decreased,and the classical prescription group was better than the routine group,the difference was statistically significant( P < 0. 05). ②BODE score: before treatment,there was no significant difference in dyspnea grade and 6-minute walking distance between the prescription group and the routine group( P > 0. 05); after treatment,the above indexes in the prescription group were significantly better than those in the routine group( P < 0. 01). ③Pulmonary function: before treatment,there was no significant difference in forced expiratory volume 1 second( FEV1),forced vital capacity( FVC),FEV1/FVC between the two groups( P < 0. 05). After treatment,FEV1,FVC and FEV1/FVC in the classical prescription group were better than those in the routine group. The difference was statistically significant( P < 0. 01). ④Hospitalization time and expenses: the hospitalization time and hospitalization expenses of classical prescription group were significantly lower than those of routine group( P < 0. 05). Conclusion: Wenyang Huayin classical prescription has a significant effect on AECOPD,which can significantly reduce the level of inflammatory factors and improve the lung function of patients.
引文
[1]GLobal strategy for the Diagnosis,Management and Prevention of COPD,Global Initiative for Chronic Obstructive Lung Disease(COPD).Revised 2017[OL].[2019-01-10].http://www.goldcopd.org
[2]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4):1-8.
[3]中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南[J].中医杂志,2012,53(1):80-84.
[4]蔡柏蔷,李龙芸.呼吸病学[M].北京:中国协和医科大学出版社,2016:1086.
[5]YIN P,WANG H D,VOS T,et al.A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013:findings from the global burden of disease study 2013[J].Chest,2016,150(6):1269-1280.
[6]慢性气道炎症性疾病气道黏液高分泌管理中国专家共识编写组.慢性气道炎症性疾病气道黏液高分泌管理中国专家共识[J].中华结核和呼吸杂志,2015,38(10):723-728.
[7]张锡纯.医学衷中参西录[M].2版.石家庄:河北科学技术出版社,2014:131-137.
[8]陈洪平.加味小青龙汤治疗老年慢性阻塞性肺疾病临床疗效观察[J].亚太传统医药,2014,10(9):120-121.
[9]郑文莲,王金环,戈艳蕾.小青龙汤加味结合西医常规疗法治疗慢性阻塞性肺疾病急性加重临床研究[J].国际中医中药杂志,2016,38(4):319-321.
[10]KIM T G,LEE Y H,LEE N H,et al.The antioxidant property of pachymic acid improves bone disturbance against AH plus-induced inflammation in MC-3T3 E1 cells[J].J Endod,2013,39(4):461-466.
[11]SCHUETZ P,ALBRICH W,MUELLER B.Procalcitonin for diagnosis of infection and guide to antibiotic decisions:Past,present and future[J].BMC Med,2011,9:107.
[12]苗云霞,阎磊.血清降钙素原水平指导AECOPD抗菌药物应用的价值[J].贵阳医学院学报,2015,40(12):1374-1380.
[13]CASALS C,ARIAS-DIAZ J,VALINO F,et al.Surfactant strengthens the inhibitory effect of C-reactive protein on human lung macrophage cytokine release[J].Am J Physiol Lung Cell Mol Physiol,2003,284(3):466-472.
[14]ROSENBERG S R,KALHAN R.Biomarkers in chronic obstructive pulmonary disease[J].Transl Res,2012,159(4):228-237.
[15]SUNDH J,JANSON C,LISSPERS K,et al.The dyspnoea,obstruction,smoking,exacerbation(DOSE)index is predictive of mortality in COPD[J].Prim Care Respir J,2012,21(3):295-301.
[16]LPEZ VARELA M V,MONTES DE OCA M,REY A,et al.Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America:The PUMA study[J].Respirology,2016,21(7):1227-1234.
[17]慢性阻塞性肺疾病评估论坛专家组.慢性阻塞性肺疾病病情严重程度评估系统在中国应用的专家共识[J].中华结核和呼吸杂志,2013,36(6):476-478.
